First Line Standard Chemo- Metastatic Biliary tract cancer
Description: Aiwu Ruth He, MD, Ph.D., discusses chemotherapy for biliary tract cancers. She recommends that patients who have progressed on standard chemotherapy enroll in a clinical trial. The NIFTY trial found nanoliposomal irinotecan plus 5-FU/leucovorin to be a promising second-line treatment in Asian patients, and a similar trial is now recruiting patients in the US and other Western countries. A trial of this therapy in patients who have failed frontline chemotherapy is open at the Ruesch Center.
Transcript:
In patients who have progressed on standard chemotherapy, who do not have any targetable genetic alterations, I would recommend those patients to be enrolled in clinical trials. At ASCO 2021, there was a randomized phase II study that evaluated the combination of NAP 5-FU leucovorin in patients who have progressed on frontline therapy have generated very promising results. Currently, at Lombardi Georgetown University Hospital, we do have a phase II study evaluating this combination in patients who have progressed on first-line standard chemotherapy. And this study is one of the studies will test the combination in Western population. The data presented at ASCO target patient in Asia, and the results was very promising. I think this is a very promising regimen, but needs further confirmation. So thatโs why weโre running the clinical trial at Lombardi.
No comments found